Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael Millward
Michael Millward
University of Western Australia
Biology
Cancer research
Wnt signaling pathway
Epithelial–mesenchymal transition
SFRP4
5
Papers
181
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and Anti-Tumor Activity.
2019
Clinical Cancer Research
Hui K. Gan
Michael Millward
Ye Hua
Chuan Qi
Yang Sai
Weiguo Su
Jian Wang
Lilin Zhang
Melanie M. Frigault
Shethah Morgan
Liu Yang
Jason D. Lickliter
Show All
Source
Cite
Save
Citations (25)
Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma
2018
Scientific Reports
Ying Dunkel
Anna L. Reid
Jason Ear
Nicolas Aznar
Michael Millward
Elin S. Gray
Robert Pearce
Melanie Ziman
Pradipta Ghosh
Show All
Source
Cite
Save
Citations (0)
A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
2017
Journal of Clinical Oncology
Michael Friedlander
Tarek Meniawy
Ben Markman
Linda Mileshkin
Paul Harnett
Michael Millward
Joanne Lundy
Alison E. Freimund
Christie Norris
John Wu
Virginia Paton
Lai Wang
Bo Gao
Show All
Source
Cite
Save
Citations (24)
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties
2015
PLOS ONE
G. Bhuvanalakshmi
Frank Arfuso
Michael Millward
Arunasalam Dharmarajan
Sunil Warrier
Show All
Source
Cite
Save
Citations (62)
1